Nanologica Strengthens Manufacturing Footprint with Södertälje Acquisition

Nanologica AB has entered into an agreement and completed the acquisition of all shares in Ardena Södertälje AB (“Syntagon”) from Ardena Sweden. The purchase price amounts to approximately SEK 8.6 million and will be paid in the form of newly issued shares in Nanologica. Syntagon is a Contract Development and Manufacturing Organization with just over 45 employees, which in 2025 had sales of approximately SEK 80 million. Nanologica believes that the acquisition will make a positive contribution to the group’s earnings already in 2026. The acquisition also strengthens Nanologica’s capacity and capabilities within production. In connection with the acquisition, Nanologica intends to raise capital in the form of a rights issue that can potentially be combined with a directed share issue. More information regarding the capital raise will be published in a separate press release when the terms of the capital raise have been approved by the Board of Directors, which is expected to take place before the stock exchange opens tomorrow. The issue of shares to the Seller shall be made at the same subscription price as the rights issue.

The transaction

Nanologica acquires all shares in Ardena Södertälje AB. The seller is Ardena Sweden AB. The acquired company will be operated as an independent wholly owned subsidiary within the Nanologica Group. Ardena Södertälje AB will take back the name Syntagon AB, under which the company was founded and under which it is known in the industry. The current CEO of Ardena Södertälje AB, Annette Roos, will remain as CEO of Syntagon AB and the business will continue to be conducted in the same premises and in a largely unchanged form.

Background and logic

Syntagon is a contract manufacturer primarily of pharmaceutical substances and possesses expertise and capacity in chemical engineering manufacturing. Syntagon has a team of just over 45 employees and is based in Södertälje. The facility specializes in API production and development, with the capacity to take active pharmaceutical ingredients (APIs) from early lead molecules to clinical studies and further into manufacturing. Nanologica has already utilized the facility for the production of silica.

Syntagon has a strong position in the Nordic region

Syntagon was founded in 1999 in Södertälje and has since built up a strong position in the development and production of small molecules on the Nordic market. After Ardena acquired the business from the founders in 2018, significant investments have been made in a modern equipment park, which has laid the foundation for the company to grow profitably in the future. The repossession of the Syntagon brand marks the return to Swedish owners and a renewed focus on Södertälje. As part of this next phase, Nanologica intends to increase the focus on sales and business development within Syntagon in order to onboard new clients and accelerate growth.

• The acquisition is expected to contribute positively to the group’s earnings in 2026 and with a stronger sales organization, Syntagon is expected to have good conditions to grow profitably.
• The acquisition strengthens Nanologica’s capacity in production and increases flexibility for business-critical medium-sized orders.
• Nanologica’s expertise in production increases and the company gets a base and infrastructure to continue to broaden the product portfolio with complementary products, in addition to silica-based purification media.
• Cost synergies of approximately SEK 4–5 million annually are expected to be achieved within 18 months of the acquisition through coordination of premises, production, and administrative functions.